Health knowledge and news provided by doctors.

Ads by Google

Schizophrenia Treatment

TorreyPines Completes Trial Of NGX267 For Treatment Of Cognitive Impairment Associated With Schizophrenia

TorreyPines Therapeutics completed its third Phase I clinical trial for NGX267, in clinical development for the treatment of cognitive impairment associated with schizophrenia (CIAS).